Latest News
Featured News
H126: solid iSCIB1+ data underpins planned progress
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Select the category
Issue of share options
Scancell to present translational data from the Phase 2 ongoing SCOPE trial of SCIB1 at the 2025 AACR IO conference
Scancell FY25 Interim Results Presentation
CEO Phil L’Huillier gives update on Scancell progress to Proactive
FY25 Interim Results: Products, People and Progress
H125 reaffirms funds are sufficient to deliver key data
Interim Results for the six months ended 31 October 2024
Notice of Interim Results
Poised for several pivotal clinical events in 2025
Scancell’s Modi-1 Moditope Vaccine Achieves Early Clinical Validation in Head and Neck Cancer
Fundraise extends cash into H226 beyond key catalysts
Genmab strikes second GlyMab deal
No results found.
JOIN OUR MAILING LIST
Sign up for news updates to stay up to date with Scancell.